Management of hypertension in peripheral arterial disease: does the choice of drugs matter?
暂无分享,去创建一个
[1] T. Nursal,et al. The prevalence and clinical predictors of incidental atherosclerotic renal artery stenosis. , 2009, European journal of radiology.
[2] Jeroen J. Bax,et al. Lower progression rate of end-stage renal disease in patients with peripheral arterial disease using statins or Angiotensin-converting enzyme inhibitors. , 2007, Journal of the American Society of Nephrology : JASN.
[3] N. Cook,et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP) , 2007, BMJ : British Medical Journal.
[4] Y. Ostchega,et al. Prevalence of Peripheral Arterial Disease and Risk Factors in Persons Aged 60 and Older: Data from the National Health and Nutrition Examination Survey 1999–2004 , 2007, Journal of the American Geriatrics Society.
[5] M. Flather,et al. Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[6] J. Powell. Intermittent claudication: a plea for guidelines for medical management. , 2007, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.
[7] J. Laragh,et al. Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: an analysis of findings from the VALUE trial , 2006, Journal of hypertension.
[8] L. Hunyady,et al. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. , 2006, Molecular endocrinology.
[9] Jeroen J. Bax,et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. , 2006, Journal of the American College of Cardiology.
[10] P. Kowey,et al. Predictors of adverse outcome among patients with hypertension and coronary artery disease. , 2006, Journal of the American College of Cardiology.
[11] S. Yusuf,et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. , 2004, European heart journal.
[12] J F Potter,et al. Extract from : , 2009 .
[13] P. Ridker,et al. Relationship between intermittent claudication, inflammation, thrombosis, and recurrent cardiac events among survivors of myocardial infarction. , 2004, Archives of internal medicine.
[14] S. Yusuf,et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease , 2004 .
[15] N. Toda. Vasodilating β-adrenoceptor blockers as cardiovascular therapeutics , 2003 .
[16] E. Boerwinkle,et al. Ethnic differences in peripheral arterial disease in the NHLBI Genetic Epidemiology Network of Arteriopathy (GENOA) study , 2003, Vascular medicine.
[17] D. Legemate,et al. Effect of β-blockers on peripheral skin microcirculation in hypertension and peripheral vascular disease , 2003 .
[18] P. Mehler,et al. Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes , 2003, Circulation.
[19] J. Östergrena,et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease , 2003 .
[20] G. Lip,et al. Treatment of hypertension in peripheral arterial disease. , 2003, The Cochrane database of systematic reviews.
[21] N. Toda. Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics. , 2003, Pharmacology & therapeutics.
[22] Peter Libby,et al. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.
[23] Jeroen J. Bax,et al. Bisoprolol reduces cardiac death and myocardial infarction in high-risk patients as long as 2 years after successful major vascular surgery. , 2001, European heart journal.
[24] P. Pattynama,et al. Incidental renal artery stenosis in peripheral vascular disease: a case for treatment? , 2001, Kidney international.
[25] G. Bray,et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet , 2001 .
[26] M. Criqui,et al. Peripheral arterial disease detection, awareness, and treatment in primary care. , 2001, JAMA.
[27] A. Hofman,et al. Determinants of peripheral arterial disease in the elderly: the Rotterdam study. , 2000, Archives of internal medicine.
[28] Giuseppe Mancia,et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT) , 2000, The Lancet.
[29] W. Mali,et al. Angiotensin Converting Enzyme Inhibitor-Induced Renal Dysfunction in Atherosclerotic Renovascular Disease , 1999 .
[30] Detection. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI) , 1997 .
[31] R. Weinshilboum,et al. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. , 1997, Archives of internal medicine.
[32] D C Hadorn,et al. Rating the quality of evidence for clinical practice guidelines. , 1996, Journal of clinical epidemiology.
[33] M. Olsen,et al. Prevalence of renal artery stenosis in patients with peripheral vascular disease and hypertension. , 1996, Journal of human hypertension.
[34] F P Cappuccio,et al. Renal artery stenosis: a common and important problem in patients with peripheral vascular disease. , 1994, The American journal of medicine.
[35] L. Ramsay,et al. beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. , 1991, BMJ.
[36] Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. , 1991, Archives of internal medicine.
[37] R. Collins,et al. Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.
[38] J. Brown,et al. Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease. , 1988, Journal of human hypertension.
[39] G. Williams,et al. NIFEDIPINE AND NOCTURIA , 1986, The Lancet.